Browse diseases

…toxicity of chimeric antigen receptor T-cell therapy (CART) for B-cell acute lymphoblastic leukemia (B-ALL). Lower rates of severe CRS have been reported in patients treat…

…CAR-T cell therapy is a major breakthrough in the management of haematologic malignancies, but its use is associated with severe adverse events requiring…

…= 53, 76%), acute lymphoblastic leukaemia (ALL, n = 6, 9%), and multiple myeloma (MM, n = 6, 9%). CAR-T products: axicabtagene ciloleucel (n = 3…

…ells targeting CD19 achieve remarkable remissions in refractory B cell malignancies, yet deleterious side effects such as cytokine release syndrome…

…Background Cytokine release syndrome (CRS) is a serious immune-related toxicity frequently associate…

…) for severity grading, with additional modules recommended for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrom…

…eading to activation of all T-cells with associated problems of cytokine release syndrome and regulatory T-cell activation. Biomunex has generated a seri…

…ng Treg activation and mitigating peripheral toxicities such as vascular leak syndrome and cytokine release syndrome. Conjugation to a human IgG4 Fc f…

…e to systemic toxicity, including cytokine release syndrome and vascular leak syndrome. Versions of IL-2 with reduced potency have been studied but re…

…peutic window and support the potential to target CDH3 positive solid tumors clinically.Ethics Approval Rodent studies were approved by the …

…oxicities. Nectin-4 has been identified as a target antigen for urothelial, colorectal, lung, breast, and other cancers because of its hig…

…ntitumor activity. While TCEs are effective in the treatment of hematological malignancies, achieving clinical antitumor activity in solid tumors has been…